Accelerating the tech-driven bioeconomy

The report outlines how the convergence of synthetic biology, AI, and biomanufacturing can transform global industries, while identifying critical barriers such as poor public perception, high scaling costs, and fragmented regional regulations.

• The technology-driven bioeconomy has significant potential for global economic impact, with synthetic biology projected to contribute to nearly $30 trillion of global manufacturing industry value by the end of the decade, representing one-third of global output.
• Convergence between digital and biological technologies is accelerating bio-innovation; specifically, the growth of patents for Large Language Models (LLMs) applied to biology is currently higher than the growth of biotechnology patents overall.
• Investment in the synthetic biology sector is heavily skewed toward healthcare and medicine, which account for 80% of overall synthetic biology investment and 63% of total venture capital investment.
• A significant barrier to adoption is the '9x effect,' where new bio-based products may need to perform nine times better than incumbent products to be adopted by consumers who tend to undervalue new benefits and overvalue existing ones.
• Downstream processing (DSP) represents a major cost bottleneck in bioproduction, potentially accounting for up to 80% of total bioproduction costs.
• Global regulatory landscapes for genetically modified organisms (GMOs) are highly inconsistent, particularly regarding 'contained use' versus 'deliberate release' laws, which dictates where specific bio-solutions can be commercialized.
• Fossil-fuel subsidies create an uneven playing field for the bioeconomy; the report states that for every subsidy allocated to a bio-based solution, five are allocated to fossil-based ones, with $8 trillion spent annually on fossil-based product subsidies.
• The bioeconomy can support significant job creation and economic growth, with the US bioeconomy adding $210 billion to GDP and generating $49 billion in wages in 2023, while the European bioeconomy adds €614 billion annually.
• Democratizing access to biotechnology in emerging economies is hindered by limited infrastructure and intellectual property concerns, though initiatives like SynbioAfrica and the Open Bioeconomy Lab are working to bridge these gaps.

APA

World Economic Forum (2024). Accelerating the tech-driven bioeconomy. https://www3.weforum.org/docs/WEF_Accelerating_the_Tech_Driven_Bioeconomy_2024.pdf

Chicago

World Economic Forum. Accelerating the tech-driven bioeconomy. 2024. https://www3.weforum.org/docs/WEF_Accelerating_the_Tech_Driven_Bioeconomy_2024.pdf.

Wikipedia

{{cite report |author=World Economic Forum |title=Accelerating the tech-driven bioeconomy |date=June 2024 |url=https://www3.weforum.org/docs/WEF_Accelerating_the_Tech_Driven_Bioeconomy_2024.pdf |access-date=23 October 2026 |via=Climate Insights Directory}}

BibTeX

@techreport{worldeconomicforum2024accelerating, author = {{World Economic Forum}}, title = {{Accelerating the tech-driven bioeconomy}}, institution = {World Economic Forum}, year = {2024}, month = jun, url = {https://www3.weforum.org/docs/WEF_Accelerating_the_Tech_Driven_Bioeconomy_2024.pdf}, urldate = {2026-10-23}, note = {Indexed by Climate Insights Directory} }